Faculty, Staff and Student Publications

Publication Date

1-17-2024

Journal

Clinical Cancer Research

DOI

10.1158/1078-0432.CCR-23-2580

PMID

37975903

PMCID

PMC10841812

PubMedCentral® Posted Date

7-17-2024

PubMedCentral® Full Text Version

Author MSS

Abstract

Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized. Activating HER2/RTK/MAPK genomic alterations appears to blunt the clinical benefit of dual anti-HER2 therapy and may hold a potential albeit partial role in patient selection. See related article by Randon et al., p. 436.

Keywords

Humans, Receptor, ErbB-2, Colorectal Neoplasms, Biomarkers, Tumor

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.